PLX
Protalix BioTherapeutics, Inc.
PLX's fundamentals are strong and it looks cheap: trading at 11x earnings, less than half its usual 26x. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
PLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PLX's revenue, profitability, cash flow and balance sheet are all currently healthy.
PLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $2.96 | — |
| Cheap | 12x | $3.21 | +8.4% |
| Fair | 26x | $6.68 | +126% |
| Expensive | 43x | $11.27 | +281% |
| Forward | 85x | $2.96 | — |
Historical ranges are pointers, not guarantees.
PLX's PE is in its cheap range at 11x. On analysts' estimates for next year's earnings, today's price would be 85x, in its expensive range.
PLX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PLX to return to profit, with revenue growing. However, they disagree widely on these estimates.
PLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.04 | -87% |
| Q3 2026 | $0.26 | +225% |
| Q2 2026 | $0.24 | +200% |
| Q1 2026 | $0.19 | +280% |
| Q4 2025 | -$0.08 | -300% |
| Q3 2025 | $0.08 | +$0.17 |
| Q2 2025 | $0.08 | +$0.24 |
| Q1 2025 | $0.05 | -38% |
| Q4 2024 | $0.04 | -56% |
PLX's earnings per share have jumped to their highest in six years: $0.26 over the past year, up from $0.08 the year before.
PLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.9M | +23% |
| Q2 2026 | $19.9M | +27% |
| Q1 2026 | $33.8M | +234% |
| Q4 2025 | $9.1M | -50% |
| Q3 2025 | $17.9M | -0.6% |
| Q2 2025 | $15.7M | +16% |
| Q1 2025 | $10.1M | +170% |
| Q4 2024 | $18.2M | +74% |
PLX's revenue is recovering but still below its 2023 peak: $22M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +6.5 points |
| Q2 2026 | 23% | +16 points |
| Q1 2026 | 63% | +104 points |
| Q4 2025 | -51% | -91 points |
| Q3 2025 | 12% | -10 points |
| Q2 2025 | 7.5% | +26 points |
| Q1 2025 | -41% | +89 points |
| Q4 2024 | 40% | +93 points |
PLX's operating margin was 18% last quarter, up 6.5 points from the same quarter a year ago.
PLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.2M | +$7.4M |
| Q2 2026 | -$11M | -$5.3M |
| Q1 2026 | $21.3M | +$26.6M |
| Q4 2025 | $1.6M | -54% |
| Q3 2025 | -$4.2M | -205% |
| Q2 2025 | -$5.7M | -$1.9M |
| Q1 2025 | -$5.4M | -249% |
| Q4 2024 | $3.6M | +6.6% |
PLX's free cash flow has turned positive again: $15M over the past year, against −$12M the year before.
PLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1M shares |
| 1 year | +3.4% | +2.8M shares |
| 3 years | -0.2% | -196K shares |
| 5 years | +84% | +38.1M shares |
| Available history | +463% | +68.7M shares |
PLX has 84M diluted shares, up 3.4% from a year ago.
PLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.9x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
| Q1 2024 | -2.9x | Net Cash |
PLX has more cash than debt.
PLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.4 | Neutral |
| Stochastic | 65.9 | Neutral |
PLX's weekly RSI is 65 (neutral) and its Stochastic is 66 (neutral).
PLX PE vs Healthcare Sector
| Metric | PLX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 56% below |
| PE % | 13 | 29 | 16 pts below |
PLX is trading at 11x earnings, a 56% discount to the Healthcare sector's median of 26x.
PLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 10% above |
| 20 week MA | $2.55 | 16% above |
| 50 week MA | $2.35 | 26% above |
| 100 week MA | $2.18 | 36% above |
| 200 week MA | $1.87 | 58% above |
PLX is in an uptrend: it's above all five of its weekly moving averages, and 58% above its 200-week average.
PLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.79 | $3.44 | +23% |
| 2021 | $3.44 | $0.95 | -72% |
| 2022 | $0.95 | $1.18 | +24% |
| 2023 | $1.18 | $1.78 | +51% |
| 2024 | $1.78 | $1.83 | +2.8% |
| 2025 | $1.83 | $1.81 | -1.1% |
| 2026 YTD | $1.81 | $2.96 | +64% |
PLX has finished higher in four of the last six years. It's up 64% so far in 2026.